Antiepileptic Drug Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Antiepileptic Drug (AED) Market
The antiepileptic drug (AED) market size was valued at USD 16.50 billion in 2023, and the market is now projected to grow from USD 17.13 billion in 2024 to USD 24.85 billion by 2032, exhibiting a CAGR of 4.8% during the forecast period of 2024-2032.
The COVID-19 pandemic negatively affected the global market due to a decline in the name for neurological tablets and offerings and issues with get admission to care. From 2022 onward, the quantity of affected person visits to neurological centers extended.Consequently, the market is expected to go lower again to its pre-pandemic boom fee from 2024 to 2032.
Despite the supply of AEDs within the marketplace, one-third of the population faces drug intolerability. Manufacturers are making efforts to cope with this issue by using developing goal-specific capsules primarily based on the neurobiology of epilepsy. The developing occurrence of epilepsy and the call for effective medicines strain market players to introduce new AEDs, with essential choices via the U.S. FDA encouraging R&D and reaping rewards sufferers.
The want to revisit widespread AED discovery and improvement is crucial to address unmet treatment desires. The patent expiration of 2d-technology capsules affords opportunities for pharmaceutical corporations to develop widely wide-spread and modern capsules. Key game enthusiasts are receiving approvals and launching 1/3-generation pills, boosting marketplace growth and inspiring funding in complicated clinical trials.
Comprehensive Analysis of Antiepileptic Drug (AED)Market
The antiepileptic drug (AED) market growth is rising at an exponential rate due to its market segmentation. This market expansion effectively provides detailed regional assessments considering the dominant supply and demand forces that impact the industry. These segmentations are methodically segregated by drug generation analysis and by distribution channel analysis. By drug generation analysis includes first generation, second generation, and third generation. By distribution channel analysis include, hospital pharmacies, retail pharmacies, and online pharmacies.
The North America region lead the antiepileptic drug (AED) market share by benefitting a market size of USD 7.97 billion in 2023 due the market in the region is characterized by higher diagnosis and treatment rates for neurology conditions.
The top players in the market play a crucial role in the industry assuring market growth and setting market standards. These players include Pfizer Inc. (U.S.), UCB S.A. (Belgium), GSK plc. (U.K.), H. Lundbeck A/S (Denmark), Eisai Co., Ltd. (Japan), Sanofi (France), Sunovion Pharmaceuticals Inc. (U.S.), Jazz Pharmaceuticals, Inc. (Ireland), these market players provide a level-playing competitive landscape.
In December 2022, Eisai Co., Ltd. Agreed to switch the U.S. Commercial rights for the antiepileptic drug (AED) Fycompa to Catalyst Pharmaceuticals, Inc., which turned into also granted an one of a kind negotiation length for an asset in Eisai’s epilepsy pipeline.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 4.8% from 2024-2032
Unit Value (USD billion)
Segmentation By Drug Generation
First Generation
Second Generation
Third Generation
ByDistribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America (By Drug Generation, By Distribution Channel, and By Country)
- U.S.
- Canada
Europe (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
Asia Pacific (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Latin America (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Incidence of Colorectal Cancer (2020) - For Key Countries, 2022/2023
- 4.2. Overview : Colorectal Cancer Screening Programs (Key Countries/ Regions)
- 4.3. New Product Approvals
- 4.4. Overview: Public Private Partnerships, Strategies Implemented by Organizations for Colorectal Cancer Screening - Key Countries
- 4.5. Number of Colorectal Cancer Screening Procedures - For Key Countries, 2022/2023
- 4.6. Average Prices of the Tests in the Market
- 4.7. Key Industry Developments (Mergers, Acquisitions, Partnerships)
- 4.8. Overview : Countries with Overburden of Colonoscopies
- 4.9. Impact of COVID-19 on the Market
- 5. Global Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Type
- 5.1.1. Stool-based
- 5.1.1.1. Fecal Immunochemical Test (FIT)
- 5.1.1.2. Fecal Occult Blood Test (FOBT)
- 5.1.1.3. Stool-DNA Test
- 5.1.2. Colonoscopy
- 5.1.3. Others
- 5.2. Market Analysis, Insights and Forecast – By End-user
- 5.2.1. Hospitals & Clinics
- 5.2.2. Clinical Laboratories
- 5.2.3. Diagnostic Imaging Centers
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast – By Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Latin America
- 5.3.5. Middle East & Africa
- 6. North America Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Type
- 6.1.1. Stool-based
- 6.1.1.1. Fecal Immunochemical Test (FIT)
- 6.1.1.2. Fecal Occult Blood Test (FOBT)
- 6.1.1.3. Stool-DNA Test
- 6.1.2. Colonoscopy
- 6.1.3. Others
- 6.2. Market Analysis, Insights and Forecast – By End-user
- 6.2.1. Hospitals & Clinics
- 6.2.2. Clinical Laboratories
- 6.2.3. Diagnostic Imaging Centers
- 6.2.4. Others
- 6.3. Market Analysis – By Country
- 6.3.1. U.S.
- 6.3.2. Canada
- 7. Europe Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Type
- 7.1.1. Stool-based
- 7.1.1.1. Fecal Immunochemical Test (FIT)
- 7.1.1.2. Fecal Occult Blood Test (FOBT)
- 7.1.1.3. Stool-DNA Test
- 7.1.2. Colonoscopy
- 7.1.3. Others
- 7.2. Market Analysis, Insights and Forecast – By End-user
- 7.2.1. Hospitals & Clinics
- 7.2.2. Clinical Laboratories
- 7.2.3. Diagnostic Imaging Centers
- 7.2.4. Others
- 7.3. Market Analysis – By Country/Sub-region
- 7.3.1. U.K.
- 7.3.2. Germany
- 7.3.3. France
- 7.3.4. Spain
- 7.3.5. Italy
- 7.3.6. Scandinavia
- 7.3.7. Rest of Europe
- 8. Asia pacific Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Type
- 8.1.1. Stool-based
- 8.1.1.1. Fecal Immunochemical Test (FIT)
- 8.1.1.2. Fecal Occult Blood Test (FOBT)
- 8.1.1.3. Stool-DNA Test
- 8.1.2. Colonoscopy
- 8.1.3. Others
- 8.2. Market Analysis, Insights and Forecast – By End-user
- 8.2.1. Hospitals & Clinics
- 8.2.2. Clinical Laboratories
- 8.2.3. Diagnostic Imaging Centers
- 8.2.4. Others
- 8.3. Market Analysis – By Country/Sub-region
- 8.3.1. China
- 8.3.2. India
- 8.3.3. Japan
- 8.3.4. Australia
- 8.3.5. Southeast Asia
- 8.3.6. Rest of Asia Pacific
- 9. Latin America Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Type
- 9.1.1. Stool-based
- 9.1.1.1. Fecal Immunochemical Test (FIT)
- 9.1.1.2. Fecal Occult Blood Test (FOBT)
- 9.1.1.3. Stool-DNA Test
- 9.1.2. Colonoscopy
- 9.1.3. Others
- 9.2. Market Analysis, Insights and Forecast – By End-user
- 9.2.1. Hospitals & Clinics
- 9.2.2. Clinical Laboratories
- 9.2.3. Diagnostic Imaging Centers
- 9.2.4. Others
- 9.3. Market Analysis – By Country/Sub-region
- 9.3.1. Brazil
- 9.3.2. Mexico
- 9.3.3. Rest of Latin America
- 10. Middle East & Africa Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast – By Type
- 10.1.1. Stool-based
- 10.1.1.1. Fecal Immunochemical Test (FIT)
- 10.1.1.2. Fecal Occult Blood Test (FOBT)
- 10.1.1.3. Stool-DNA Test
- 10.1.2. Colonoscopy
- 10.1.3. Others
- 10.2. Market Analysis, Insights and Forecast – By End-user
- 10.2.1. Hospitals & Clinics
- 10.2.2. Clinical Laboratories
- 10.2.3. Diagnostic Imaging Centers
- 10.2.4. Others
- 10.3. Market Analysis – By Country/Sub-region
- 10.3.1. GCC
- 10.3.2. South Africa
- 10.3.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Company Share Analysis for Stool-based Tests, 2023
- 11.2. Company Share Analysis for Colonoscopes, 2023
- 11.3. Company Profiles
- 11.3.1. NOVIGENIX SA
- 11.3.1.1. Overview
- 11.3.1.2. Products & Services
- 11.3.1.3. SWOT Analysis
- 11.3.1.4. Recent Developments
- 11.3.1.5. Strategies
- 11.3.1.6. Financials (Based on Availability)
- 11.3.2. EIKEN CHEMICAL CO., LTD.
- 11.3.2.1. Overview
- 11.3.2.2. Products & Services
- 11.3.2.3. SWOT Analysis
- 11.3.2.4. Recent Developments
- 11.3.2.5. Strategies
- 11.3.2.6. Financials (Based on Availability)
- 11.3.3. Clinical Genomics Technologies Pty Ltd.
- 11.3.3.1. Overview
- 11.3.3.2. Products & Services
- 11.3.3.3. SWOT Analysis
- 11.3.3.4. Recent Developments
- 11.3.3.5. Strategies
- 11.3.3.6. Financials (Based on Availability)
- 11.3.4. Exact Sciences Corporation
- 11.3.4.1. Overview
- 11.3.4.2. Products & Services
- 11.3.4.3. SWOT Analysis
- 11.3.4.4. Recent Developments
- 11.3.4.5. Strategies
- 11.3.4.6. Financials (Based on Availability)
- 11.3.5. Epigenomics AG
- 11.3.5.1. Overview
- 11.3.5.2. Products & Services
- 11.3.5.3. SWOT Analysis
- 11.3.5.4. Recent Developments
- 11.3.5.5. Strategies
- 11.3.5.6. Financials (Based on Availability)
- 11.3.6. bioMérieux, Inc.
- 11.3.6.1. Overview
- 11.3.6.2. Products & Services
- 11.3.6.3. SWOT Analysis
- 11.3.6.4. Recent Developments
- 11.3.6.5. Strategies
- 11.3.6.6. Financials (Based on Availability)
- 11.3.7. OLYMPUS CORPORATION
- 11.3.7.1. Overview
- 11.3.7.2. Products & Services
- 11.3.7.3. SWOT Analysis
- 11.3.7.4. Recent Developments
- 11.3.7.5. Strategies
- 11.3.7.6. Financials (Based on Availability)
- 11.3.8. KARL STORZ SE & Co. KG
- 11.3.8.1. Overview
- 11.3.8.2. Products & Services
- 11.3.8.3. SWOT Analysis
- 11.3.8.4. Recent Developments
- 11.3.8.5. Strategies
- 11.3.8.6. Financials (Based on Availability)
- 11.3.9. FUJIFILM Holdings America Corporation
- 11.3.9.1. Overview
- 11.3.9.2. Products & Services
- 11.3.9.3. SWOT Analysis
- 11.3.9.4. Recent Developments
- 11.3.9.5. Strategies
- 11.3.9.6. Financials (Based on Availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook